| 1 |
Approval Pathways for Small-Molecule Drugs |
| 2 |
Global Pharmaceutical Sales (Conventional Vs Biologics), ($Billion) |
| 3 |
Global Pharmaceutical Sales (Conventional Vs Biologics) % share ($Billion) |
| 4 |
Top Pharmaceutical Market |
| 5 |
Top Biologics Market |
| 6 |
Global Biologic Drug Sales ($Billion) |
| 7 |
Growth Rate: Patented Biologics Vs Biosimilars |
| 8 |
Market Revenue: Patented Biologics Vs Biosimilars ($Billion) |
| 9 |
Biologic Molecule Scenarios in the U.S. after Biosimilar Introduction |
| 10 |
Global Biologics Drugs Market by Class, ($Billion) |
| 11 |
Global Biologic Drugs Market , 2016 |
| 12 |
Global Biologic Drugs Market , 2025 |
| 13 |
Biologic Drugs by Indications, ($Billion) |
| 14 |
Biologic Drugs by Indications, 2016 |
| 15 |
Biologic Drugs by Indications, 2025 |
| 16 |
Investigational Biologics by Indications |
| 17 |
Global Biologic Drugs Market: Regional Prospective |
| 18 |
Global Biologic Drugs Demand, 2016 |
| 19 |
Global Biologic Drugs Market by Region, $Billion |
| 20 |
Global Biologic Drugs Market by Region, 2016 |
| 21 |
Global Biologic Drugs Market by Region, 2025 |
| 22 |
Research Methodology |
| 23 |
Data Triangulation |
| 24 |
Key Data Points From Secondary Sources |
| 25 |
Key Data Points From Primary Sources |
| 26 |
Top-Down Approach (Segmental Analysis) |
| 27 |
Bottom-Up Approach (Segmental Analysis) |
| 28 |
Assumptions and Limitations |
| 29 |
Clinical Trail Products Type Share by Therapeutic Areas |
| 30 |
Global Biologics Market Size Therapeutic Areas, 2016 and 2025, ($Billion) |
| 31 |
Global Oncology Biologics Products Market Size, 2014-2025, ($Billion) |
| 32 |
Global Cardiovascular Biologics Products Market Size, 2014-2025, ($Billion) |
| 33 |
Global Market Size of Products for Immunological Diseases, 2014-2025 ($Billion) |
| 34 |
Global Market Size of Products for Infectious Diseases, 2014-2025 ($Billion) |
| 35 |
Global Market Size of Products for Metabolic Diseases, 2014-2025, ($Billion) |
| 36 |
Global Market Size of Products , 2014-2025, ($Billion) |
| 37 |
Different Types of Biologics or Biopharmaceuticals |
| 38 |
Global Biopharmaceutical Market Size, 2014 and 2025, ($Billion) |
| 39 |
Global mAbs Market Size, 2014 and 2025 ($Billion) |
| 40 |
Market Size of Top mAbs Products, 2014 and 2025 ($Billion) |
| 41 |
Global Hormones Market Size, 2014 and 2025 ($Billion) |
| 42 |
Market Size of Top Hormone Products, 2014 and 2025 ($Billion) |
| 43 |
Global Growth Factors Market Size, 2014 and 2025, ($Billion) |
| 44 |
Market Size of Top Growth Factor Products, 2014 and 2025 ($Billion) |
| 45 |
Global Fusion Proteins Market Size, 2014 and 2025 ($Billion) |
| 46 |
Market Size of Top Fusion Protein Products, 2014 and 2025, ($Billion) |
| 47 |
Global Cytokine Market Size, 2014 and 2025, ($Billion) |
| 48 |
Market Size of Top Cytokine Products, 2014 and 2025 ($Billion) |
| 49 |
Global Therapeutic Enzymes Market Size, 2014 and 2025, ($Billion) |
| 50 |
Market Size of Top Therapeutic Enzyme Products, 2014 and 2025, ($Million) |
| 51 |
Global Blood Factors and Anticoagulants Market Size, 2014 and 2025, ($Billion) |
| 52 |
Market Size of Top Blood Factors and Anticoagulant Products, 2014 and 2025, ($Billion) |
| 53 |
Global Vaccines Market Size, 2014 and 2025 ($Billion) |
| 54 |
Market Size of Top Recombinant Vaccines, 2014 and 2025 ($Billion) |
| 55 |
Global Scenario |
| 56 |
Figure: North America Biologic Market Size, 2014 and 2025 ($Billion) |
| 57 |
Country Analysis, North America |
| 58 |
Europe Biologics Market Size, 2014 and 2025, ($Billion) |
| 59 |
Country Analysis, Europe |
| 60 |
Asia Pacific Biologic Market Size, 2014 and 2025 ($Billion) |
| 61 |
Country Analysis, Asia Pacific |
| 62 |
Latin America Biologic Market Size, 2014 and 2025, ($Billion) |
| 63 |
Country Analysis, Latin America |
| 64 |
Share of Key Development and Strategies |
| 65 |
Total Number of Strategies and Developments |
| 66 |
AbbVie Inc.:Product Portfolio |
| 67 |
Financials |
| 68 |
AbbVie Inc.: Net Sales by Geographic Destination (2014-2016) |
| 69 |
AbbVie Inc. : SWOT Analysis |
| 70 |
Allergan Plc: Product Portfolio |
| 71 |
Financials |
| 72 |
Allergan Plc: Net Sales by Business Segments (2015-2016) |
| 73 |
Allergan Plc: Net Sales by Business Segment (2014) |
| 74 |
Allergan Plc: SWOT Analysis |
| 75 |
Amgen Inc.: Product Portfolio |
| 76 |
Amgen Inc. : Overall Financials (2014-2016) |
| 77 |
Amgen Inc. : Net Sales by Geographic Destination (2014-2016) |
| 78 |
Amgen Inc. : SWOT Analysis |
| 79 |
Astellas Pharma Inc. : Overall Financials (2014-2016) |
| 80 |
Astellas Pharma Inc. : Net Sales by Product Type (2014-2016) |
| 81 |
Astellas Pharma Inc. : Net Sales by Geographic Destination (2014-2016) |
| 82 |
Astellas Pharma Inc. : SWOT Analysis |
| 83 |
AstraZeneca PLC: Product Portfolio |
| 84 |
AstraZeneca PLC : Overall Financials, 2014-2016 |
| 85 |
AstraZeneca PLC : Net Revenue by Business Segment, 2014-2016 |
| 86 |
AstraZeneca PLC : Revenue across Different Geographies, 2014-2016 |
| 87 |
AstraZeneca PLC: SWOT Analysis |
| 88 |
Bayer AG: Product Portfolio |
| 89 |
Bayer AG : Overall Financials, 2014-2016 |
| 90 |
Bayer AG : Net Revenue by Business Segment, 2014-2016 |
| 91 |
Bayer AG: Net Revenue by Geographic Destination, 2014-2016 |
| 92 |
Bayer AG: SWOT Analysis |
| 93 |
Biocon Ltd.: Product Portfolio |
| 94 |
Biocon Ltd. : Overall Financials, 2015-2017 |
| 95 |
Biocon Ltd.: Net Revenue by Business Segment, 2015-2017 |
| 96 |
Biocon Ltd. : Net Revenue by Pharma Business Segment, 2014-2016 |
| 97 |
Biocon Ltd. : Revenue across Different Geographies, 2014-2016 |
| 98 |
Biocon Ltd.: SWOT Analysis |
| 99 |
Boehringer Ingelheim GmbH: Product Portfolio |
| 100 |
Boehringer Ingelheim GmbH : Overall Financials (2014-2016) |
| 101 |
Boehringer Ingelheim GmbH : Net Sales by Product Type (2014-2016) |
| 102 |
Boehringer Ingelheim GmbH : Net Sales by Geographic Destination (2014-2016) |
| 103 |
Boehringer Ingelheim GmbH: SWOT Analysis |
| 104 |
BRISTOL-MYERS SQUIBB COMPANY: Product Portfolio |
| 105 |
BRISTOL-MYERS SQUIBB COMPANY: Overall Financials (2014-2016) |
| 106 |
BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Product Type (2014-2016) |
| 107 |
BRISTOL-MYERS SQUIBB COMPANY: Net Sales by Geographic Destination (2014-2016) |
| 108 |
BRISTOL-MYERS SQUIBB COMPANY: SWOT Analysis |
| 109 |
Eli Lilly and Company: Product Portfolio |
| 110 |
Eli Lilly and Company : Overall Financials (2014-2016) |
| 111 |
Eli Lilly and Company : Net Sales by Product Type (2014-2016) |
| 112 |
Eli Lilly and Company : Net Sales by Geographic Destination (2014-2016) |
| 113 |
Eli Lilly and Company: SWOT Analysis |
| 114 |
F. Hoffmann-La Roche AG : Product Portfolio |
| 115 |
Roche AG: Overall Financials, (2013–2016) |
| 116 |
Roche AG: Revenue across Different Geographies, (2013-2016) |
| 117 |
Roche AG: Net Revenue by Business Segment, (2013-2016) |
| 118 |
Roche AG: SWOT Analysis |
| 119 |
GILEAD SCIENCES, INC.: Product Portfolio |
| 120 |
GILEAD SCIENCES, INC. : Overall Financials (2014-2016) |
| 121 |
GILEAD SCIENCES, INC. : Net Sales by Geographic Destination (2014-2016) |
| 122 |
GILEAD SCIENCES, INC. : SWOT Analysis |
| 123 |
GlaxoSmithKline Plc: Product Portfolio |
| 124 |
GSK: Overall Financials (2013-2016) |
| 125 |
GSK: Net Revenue by Business Segments (2013-2016) |
| 126 |
GSK: Net Revenue by Geography (2013-2015) |
| 127 |
GSK: Net Revenue by Geography (2016) |
| 128 |
GlaxoSmithKline Plc: SWOT Analysis |
| 129 |
JOHNSON & JOHNSON: Product Portfolio |
| 130 |
JOHNSON & JOHNSON: Overall Financials (2014-2016) |
| 131 |
JOHNSON & JOHNSON : Net Revenue by Business Segment (2014-2016) |
| 132 |
JOHNSON & JOHNSON : Net Revenue by Region (2014-2016) |
| 133 |
JOHNSON & JOHNSON: SWOT Analysis |
| 134 |
Merck & CO., Inc.: Product Portfolio |
| 135 |
Merck & CO., Inc.: Overall Financials (2013-2016) |
| 136 |
Merck & CO., Inc.: Net Revenue by Business Segments (2013-2014) |
| 137 |
Merck & CO., Inc.: Net Revenue by Business Segments (2015-2016) |
| 138 |
Merck & CO., Inc.: Net Revenue by Geography (2013-2014) |
| 139 |
Merck & CO., Inc.: Net Revenue by Geography (2015-2016) |
| 140 |
Merck & Co., Inc. : SWOT Analysis |
| 141 |
Merck & CO., Inc. KGaA: Overall Financials, (2014-2016) |
| 142 |
Merck & CO., Inc. KGaA: Net Revenue by Business Segments, (2014-2016) |
| 143 |
Merck & CO., Inc. KGaA: Net Revenue by Geography, (2014) |
| 144 |
Merck & CO., Inc. KGaA: Net Revenue by Geography, (2015-2016) |
| 145 |
Merck KGaA : SWOT Analysis |
| 146 |
Novartis AG: Product Portfolio |
| 147 |
Novartis: Overall Financials (2013-2016) |
| 148 |
Novartis: Net Revenue by Business Segments, (2013-2014) |
| 149 |
Novartis: Net Revenue by Business Segments (2015-2016) |
| 150 |
Novartis: Net Revenue by Geography (2013-2016) |
| 151 |
Novartis AG: SWOT Analysis |
| 152 |
NOVO NORDISK: Product Portfolio |
| 153 |
Novo Nordisk: Overall Financials, 2014-2016 |
| 154 |
Novo Nordisk: Net Revenue by Business Segment, 2014-2016 |
| 155 |
Novo Nordisk: Revenue across Different Geographies, 2014-2016 |
| 156 |
NOVO Nordisk: SWOT Analysis |
| 157 |
Pfizer Inc.: Product Portfolio |
| 158 |
Pfizer: Overall Financials (2013-2016) |
| 159 |
Pfizer: Net Revenue by Geography (2013-2016) |
| 160 |
Pfizer: Net Revenue by Business Segments (2013-2014) |
| 161 |
Pfizer: Net Revenue by Business Segments (2015-2016) |
| 162 |
Pfizer Inc. : SWOT Analysis |
| 163 |
Sanofi: Product Portfolio |
| 164 |
Sanofi: Overall Financials (2014-2016) |
| 165 |
Sanofi: Net Sales by Business Segments (2014-2016) |
| 166 |
Sanofi: Net Sales by Geographic Destination (2014-2016) |
| 167 |
Sanofi: Net Sales by Franchise (2014-2016) |
| 168 |
Safoni: SWOT Analysis |
| 169 |
Teva Pharmaceuticals Industries Limited.: Product Portfolio |
| 170 |
Teva Pharmaceutical Industries Limited: Overall Financials, (2013-2016) |
| 171 |
Teva Pharmaceutical Industries Limited : Net Revenue by Business Segments, (2013-2016) |
| 172 |
Teva Pharmaceutical Industries Limited: Net Revenue by Geography, (2013-2016) |
| 173 |
Teva Pharmaceutical Industries Ltd.: SWOT Analysis |
